| Symptomatic toxicities associated with anticancer treatments, such as nausea and vomiting, are frequently underreported by clinicians, even when data are prospectively collected within clinical trials. Such underreporting can result in an underestimation of the absolute rate of toxicity, which is highly relevant information for patients and their physicians in clinical practice, and for regulatory authorities. Systematic collection of patient-reported outcomes (PROs) has been demonstrated to be a valid, reliable, feasible and precise approach to tabulating symptomatic toxicities and enables symptoms that are missed by clinicians to be detected. In this Perspectives, the barriers and challenges that should be addressed when considering broad integration of PRO toxicity monitoring in oncology clinical trials are discussed, including challenges related to data collection logistics, analytical approaches, and resource utilization. Instruments conceived to enable description of treatment-related adverse effects, from the patient perspective, bring the potential to improve risk-versus-benefit analyses in clinical research, and to provide patients with accurate information, on the basis of previous experiences of their peers. NATURE REVIEWS | CLINICAL ONCOLOGY VOLUME 13 | MAY 2016 | 319 PERSPECTIVES © 2 0 1 6 M a c m i l l a n P u b l i s h e r s L i m i t e d . A l l r i g h t s r e s e r v e d .
Knowledge of the potential benefits and risks associated with the use of anticancer therapies is fundamental for making treatment-related recommendations and decisions. This information is vital to multiple stakeholders, including regulatory authorities, clinical researchers, clinicians and most of all, patients. In the regulatory process for the authorization of new medicinal products, both the FDA in the USA 1 and the EMA in Europe 2 have published frameworks for conducting benefit versus risk evaluations that rely on the results of qualitative analyses and the judgment of experts based upon the available clinical data, which is usually (but not necessarily) obtained from randomized controlled clinical trials. Benefit is measured in terms of therapeutic efficacy, evaluated according to the primary end points that the studies were designed and powered to provide measurements of, such as overall survival or progression-free survival 3 .
experiences of the patient (including symptoms such as diarrhoea, fatigue and pain). A risk of underreporting or failing to detect subjective toxicities might occur when adverse events are quantified using the CTCAE system for several reasons: these relate both to clinician factors (such as if the clinician considers the patient's symptoms unrelated to the treatment, or pays less attention in reporting mild symptoms) and/or to more complex aspects of the interactions and communication between clinicians and patients (such as if the clinician does not ask about toxicities that are not commonly associated with that treatment, or if the patient, when asked, does not mention the toxicity). Furthermore, use of this indirect method of reporting a symptom increases the risk of errors in interpretation along the way to final codification as a graded CTCAE in the clinical trial database. According to the FDA definition, clinician-reported outcomes involve "clinical judgment or interpretation of the observable signs, behaviours, or other physical manifestations thought to be related to a disease or condition, and cannot directly assess symptoms that are known only to the patient" (REF. 5 ).
Reporting by clinicians
Reporting of adverse events by the healthcare provider, using the CTCAE, has been demonstrated to have a low level of inter-investigator reliability 6 , and to miss up to half of a patients' symptoms compared with direct accounts of adverse events provided by the patients themselves 7 . Moreover, compared with patient-reported outcomes (PROs), toxicity reports provided by healthcare professionals have been demonstrated to be less concordant with a patient's overall health status 8 . Of course, as described elsewhere, not all toxicities are amenable to reporting by patients 9 . For example, objective toxicities that can be measured using laboratory tests (such as neutropenia), or observable phenomena (such as retinal detachment), are best reported by qualified healthcare practitioners. However, as noted by the FDA 10 , subjective experiences such as symptoms are best known by the individual patient who is, therefore, best Risk assessment, or measuring the risk of harm from anticancer therapy, is based largely on toxicity information garnered from clinical trials; thus far, reporting of adverse events by investigators, according to the Common Terminology Criteria for Adverse Events (CTCAE) has been the most widely used method of quantifying harm from treatment experienced by patients 4 . The CTCAE defines the terms of individual adverse events and provides a grading scale for the severity of each item. Some adverse events might be measurable using laboratory-based and/or other examinations (for example, anaemia or QT prolongation), and others from direct clinician observations or measurements (for example, maculopapular rash or hypertension). However, approximately 10% of the adverse event items in the CTCAE are symptomatic toxicities that, in order to be reported, require that the clinician documents and then grades the subjective placed to optimally report the occurrence of clinically relevant adverse events without 'filtering' of this information by a healthcare professional.
Patient-reported outcome measures
Over the past decade, interest has grown in the potential integration of PROs as part of routine toxicity data collection and reporting of adverse events in clinical trials 7, 11 . A PRO is defined as a measurement of the patient's condition, reported directly by the patient, without interpretation by a clinician or anyone else. Symptom-related items in quality-of-life (QoL) instruments, validated symptom scales, and more recently a PRO version of the CTCAE, which was developed by the US National Cancer Institute (NCI), have particular value in trials designed to investigate oral cancer therapies, where outpatient compliance is a known issue 15 ; thus, understanding the true incidence of symptomatic toxicities early in the drug-development process might be useful. Many examples of patients discontinuing oral medicines owing to the occurrence of bothersome symptomatic toxicities currently exist (such as discontinuation of aromatase inhibitors owing to arthralgias) 16 . PRO measures of adverse events might also be especially useful in clinical trials designed to test the efficacy of precision medicine, and in first-in-man trials, where usually only limited insights into effects of a drug on a patient's general health are available. For example, trials of immunotherapies, such as provide the means for collecting unfiltered information regarding symptomatic toxicities directly from patients 12 .
The FDA and EMA have both provided guidance on the use of PROs in clinical trials 10, 13 and the EMA provides guidance regarding the use of PROs in trials of anticancer drugs 14 , further underlining the importance of including the patient's perspective as a standard outcome measure, and as an essential source of information when evaluating the benefits and harms of cancer therapeutics. Of note, the FDA advocates that symptoms or other unobservable concepts known only to the patient (such as nausea or pain severity) can be measured adequately only using PRO measures 5 . Patient-reported toxicities might drugs with mechanisms related to cytotoxic T-lymphocyte-associated protein 4 (CTLA4) or programmed cell death protein 1 (PD-1), which can have clinically relevant, and sometimes unpredictable toxicities 17 (including fatigue, colitis that might become clinically apparent with diarrhoea, or pneumonitis that might begin with shortness of breath, cough, or chest pain) would likely benefit from the use of PRO measures.
Patient and clinician agreement PRO measures are widely considered to be the gold standard for the assessment of subjective symptoms, as patients are in the best position to comment on their own subjective experiences 10, 13 . Findings of several published studies have consistently demonstrated that health professionals underestimate the incidence and severity of their patients' symptoms, when compared with PROs, with only slight to fair agreement (when measured by κ coefficient), or with underreporting typically observed in more than half of the patients, for many symptoms [18] [19] [20] [21] . More specifically, a number of publications have focused on the comparison of patients' and clinicians' reporting of the treatment-related adverse events experienced by cancer patients, consistently demonstrating underreporting of adverse events by clinicians [22] [23] [24] [25] (TABLE 1) .
Overall, across study reports in the published literature, clinicians consistently and substantially underreport both the prevalence and severity of patients' symptoms compared with the direct reports provided by the patients themselves [22] [23] [24] [25] . For example, Fromme and colleagues 22 analysed data collected in a prospective clinical trial evaluating the safety and efficacy of weekly calcitriol and docetaxel in patients with metastatic androgen-independent prostate cancer. The researchers found that reporting of common treatmentrelated adverse effects of chemotherapy by clinicians was neither sensitive nor specific: overall sensitivity and specificity of clinician reporting relative to PROs obtained using the Quality-of-Life Questionnaire C30 was 47% and 68%, respectively 22 . Patients and clinicians agreed on the absence of a symptom in 102 of 254 (40%) possible instances, with a Cohen's-κ coefficient of 0.15, indicating poor agreement between the two methods of detecting adverse events.
In the study by Fromme et al. 22 , the comparison of patients' and clinicians' reporting of adverse events was based on different instruments, as clinicians used the NCI Common Toxicity Criteria (version 2.0) for breast, colorectal or other tumours 24 , agreement between patients and nurses on the incidence of treatment-related adverse events was generally stronger than that between patients and clinicians. In detail, κ coefficients measuring agreement between patient-reported and nurse-reported events were higher than those between patients and clinicians for five out of the six most common adverse events: asthenia (0.75 versus 0.37 respectively), constipation (0.83 versus 0.45), neuropathy (0.82 versus 0.55), mucositis (0.78 versus 0.46) and diarrhoea (0.90 versus 0.77). The only exception was nausea, where the κ coefficient measuring agreement with patients was very good for both nurses and clinicians (0.91 versus 0.89, respectively) 24 . On the basis of these results, the authors suggested that nurses should be employed in collecting data on treatment toxicities, because they showed better performance than doctors in reporting information from the patients.
Given the prospective designs of these studies 23, 24 , it is worth noting that clinicians, although blinded to patients' answers, were aware that their report would have been subsequently compared with their patient's report; the extent of underreporting by clinicians, when they are not aware of the comparison with the patient's report, could be substantially higher. In a pooled analysis of data from three randomized and not the QLQ-C30. However, even in several studies 23, 24 where comparisons between patients' and clinicians' reporting of adverse events has been assessed using the same instrument, results have indicated the risk of underreporting by clinicians. For example, Basch and colleagues 23 , prospectively compared reporting of symptom occurrence and severity by outpatients with either lung (non-small-cell or small-cell) or genitourinary cancers with symptom reporting by clinicians. Both patients' and clinicians' reports were based on the CTCAE; the items completed by clinicians remained unchanged in the questionnaire, whereas the patientcompleted version included identical items with syntactical modifications in order to improve comprehension. The agreement between clinicians and patients in the incidence and severity of symptoms was high for symptoms that can be better 'quantified' , such as vomiting (89% and 96% for patients with lung or genitourinary cancers, respectively) or diarrhoea (85% for both patient groups) 23 . However, agreement was low for subjective symptoms such as fatigue (41% and 55% for patients with lung or genitourinary cancers, respectively) and dyspnoea (52% for patients with lung cancer). In a similar study conducted in Italy among outpatients who received different types of chemotherapy trials 25 , patients' and clinicians' reporting of six toxicities (anorexia, nausea, vomiting, constipation, diarrhoea and hair loss) experienced during anticancer treatment were subsequently compared. Agreement between patients and clinicians was low (with Cohen's-κ coefficient ranging between 0.15 and 0.45, which can be interpreted as poor to moderate agreement), and toxicity rates based on clinicians' reports were consistently lower than those reported by the patients themselves: the extent of underreporting of specific toxicities by clinicians ranged from 41% for nausea to 74% for appetite loss 25 (FIG. 1) .
A systematic description of the factors potentially explaining the underreporting of treatment toxicities by health professionals is not currently available in the literature, although we have listed and commented on fatigue or appetite loss are both common observations in patients with cancer, especially in patients with advanced-stage disease. Alternatively, peripheral neurotoxicity or hair loss could be a result of residual toxicity from previous treatments. However, we believe that this explanation is far less likely for the occurrence of many adverse events, such as nausea and vomiting, or diarrhoea, which can be prudently considered treatment-related in the majority of patients.
Clinicians might also pay less attention to the reporting of mild toxicities, particularly those effects that would not prompt a need for treatment modification or supportive care. However, an accurate evaluation of the risk-benefit ratio of a treatment should be based on complete reporting of toxicities, and should include toxicities of all grades (even grade 1 toxicities), particularly if long-lasting. Furthermore, available data suggest that underreporting can occur even when patients describe severe toxicity 25 .
In the comparison of patient-reported and clinician-reported adverse effects, when the analysis was limited to patients who reported 'very much' toxicity in any cycle, it showed that the proportion of underreporting by clinicians was lower, as expected, compared to the analysis of 'any grade' toxicity; notwithstanding, this reduction in underreporting remains clinically relevant, with the extent of this effect ranging from 13.0% for vomiting to 50.0% for anorexia 25 (FIG. 1) .
Underreporting of adverse events could also be the result of poor communication between patients and health professionals, resulting in the failure to acquire all the correct information on the occurrence of toxicity (TABLE 2) . In this situation, underreporting could lead to a risk of suboptimal management of the symptoms. If a specific toxicity is largely expected with the drug that the patient is receiving, clinicians could, paradoxically, pay less attention to the reporting of this toxicity. However, at least in principle, the opposite could also be true because clinicians could be more accurate in asking patients about toxicities that are largely expected. In the TORCH trial, in which investigators compared the efficacy of erlotinib to that of cisplatin plus gemcitabine as a first-line treatment of patients with advanced-stage non-small-cell lung cancer, the rate of underreporting of nausea, vomiting and diarrhoea suggests that clinicians are more accurate in reporting treatment-related adverse effects that are expected with the use of each the most likely, relevant factors (TABLE 2) . Factors explaining the underreporting of toxicities can be divided into two groups: in the first group, information about toxicities is correctly acquired but not reported, while in the second group, underreporting is the consequence of poor communication between the patient and their clinician.
In some cases, information regarding treatment toxicities, although not explicitly reported, could still have been correctly acquired by health professionals. According to our experience, the lack of reporting could result from a decision not to report the symptoms that were already present before the start of treatment, or those judged unrelated to treatment, but related to exposure to previous treatments or caused by the disease itself. This situation could be true for some adverse events: for instance, Erlotinib specific treatment than those that are not expected 25 (FIG. 2) . In detail, underreporting of nausea and vomiting was higher in patients receiving erlotinib compared with those receiving chemotherapy, the latter approach is expected to produce more emesis than treatment with erlotinib. Conversely, the underreporting of diarrhoea was higher with cisplatin plus gemcitabine than with erlotinib, and treatment using erlotinib is, indeed, typically expected to result in more diarrhoea than treatment with chemotherapy. If clinicians correctly acquire information about a toxicity but under-document the incidence, the implications for clinical management might be minimal, but there would be several substantial implications for clinical trial tabulation. Underreporting of toxicities in clinical trials and resulting publications, possibly resulting in incorrect drug labelling might subsequently lead to future patients not deriving the optimal level of benefit that a medicinal product might have. Moreover, an opportunity for adverse-event management programmes is missed, and patient compliance with treatments might be negatively affected. By contrast, if underreporting is caused by underdetection, for example owing to communication barriers between patients and clinicians, this might lead to a risk of both suboptimal toxicity management and suboptimal tabulation of adverse events.
PROs in routine toxicity description
Several barriers to integration of PROs into routine toxicity collection in oncology clinical trials currently exist, and various solutions have been suggested and tested 7,9 . In terms of data collection, concerns have been raised that completion rates might be low, particularly from patients who are very ill, or from those with end-stage disease owing to substantially impaired functional status near the end of life. Feasibility assessments embedded in multiple clinical trials have now demonstrated sustained patient compliance rates of approximately 90% during active therapy, including among those with impaired performance status [26] [27] [28] . Patient survey response rates can be optimized through a number of approaches 29 . Firstly, patients are more likely to respond if they know that their report is an important part of a clinical trial, that the PROs are requested by their doctor and nurse and that the information will likely be of benefit to future patients 29 . These messages can be conveyed to the patient analysis of cumulative incidence of toxicities (this would be coded as zero). However, if the patient entered with grade 2 nausea, but then reported nausea that was deemed to be of a more severe grade (such as grade 3) during the trial, this would be recorded as a grade 3 toxicity. This approach generally lowers the measured cumulative incidence of adverse events, particularly for symptoms that are prevalent at baseline 27 .
Memory degradation is a concern, which might affect the accuracy of PRO measures, as patients' recall of symptoms can begin to fade within about a week of the symptom occurring 32 . Therefore, weekly patient reporting should, ideally, be employed during any period of active treatment in a clinical trial, using electronic data capture whenever possible. However, data collection every 2-3 weeks can also be considered if necessary for a particular trial design, with an adjusted recall period (such as a questionnaire conducted every 2 weeks, with a recall period over the past two weeks), with an understanding that some additional measurement errors will likely be introduced 33 .
during informed consent and training in use of PROs. Secondly, PRO questionnaires need to be brief and easy to complete. Thirdly, compliance should be monitored in real time, with backup data collection for non-responders, for example via a telephone call. Backup data collection has been demonstrated to improve compliance rates by 10-15% overall [27] [28] [29] .
The logistics of PRO data collection have also been evaluated, revealing that high compliance rates of around 90-100% can be obtained using in-clinic tablet computers or paper questionnaire administration and between-visit web, or between-visit interactive voice response (IVR) automated telephone systems, compared to much lower historic compliance rates with use of paper forms, which are much lower than 90-100% 9 . Input from the investigative team at data collection sites is minimal, and is generally restricted to providing initial training to patients and reminding patients to report their adverse events 30 . When between-visit reporting is employed, a central data management team can take over the responsibility of issuing of reminders and troubleshooting in order to remove this burden from the local team. In previous trials, less than 1% of on-site data management time for any given trial has been consumed by these activities 28, 31 .
Analysis of PRO data
In terms of analyses, an ongoing debate exists on whether or not baseline symptom scores should be considered when reporting toxicities 27 . Patients often enter clinical trials with baseline symptoms related either to their cancer, to prior treatments, to other comorbidities or to a combination of these factors. Use of PRO measures results in detection of more of these baseline symptoms than reporting of toxicities by clinicians 27 . PROs, therefore, offer an opportunity to control for baseline (pre-existing) symptoms in assessments of toxicity in order to identify those events that are most likely not to be pre-existing. Indeed, regulatory agencies commonly evaluate the occurrence of treatmentrelated adverse events using this approach; although, use of this approach is less common for investigators when reporting trial results (such as when simple cumulative incidence numbers are provided in toxicity tables). The approach to considering baseline symptoms is as follows: if a patient enters a trial with grade 2 nausea, and experiences grade 2 nausea during the trial, that toxicity would not be counted in an Reconciliation with investigator reports is one of the most substantial challenges in this area. No consensus currently exists on the best approach to reconciliation, although several approaches have been suggested. One approach (FIG. 3a) is to share patient reports with investigators in real time, at the point of care, so that investigators can make use of this information in patient management. This approach has been tested in prior clinical research, and it has been reported that patient-investigator agreement increases to >90%, compared with the poor to moderate agreement consistently reported in the past for many adverse events 27, 34 . Alternatively, patient and investigator reports can be collected separately and reconciled at the time of data analysis (FIG. 3b) , with site queries about discrepancies in paired data and selection of the report that indicates the most severe toxicities of the two at any given time. If this approach is employed, ideally the baseline symptom scores will be considered. A third potential approach (FIG. 3c) is to collect the information separately and not reconcile it, but simply present the patient and investigator reports side by side 27 .
The final challenge to implementation of PROs relates to research culture and historical precedent. Patients have not traditionally reported on toxicities, and some investigators believe that patients might either exaggerate or underestimate their own symptom burdens. However, this perspective is not consistent with the current thinking of experts serving on regulatory bodies or with the available empirical evidence 10, 13, 14 .
in which information on patient-reported toxicities was shared with investigators, those investigators' CTCAE reports were found to be more in line with patient's reports of toxicities 34, 37 . Moreover, in these evaluations 34, 37 , patient self-reports identified more baseline symptoms than clinicians, enabling improved analyses of which symptoms were emergent during trials.
The totality of this evidence suggests that, although clinician CTCAE reporting has clinical value and is feasible, patient reporting enables greater precision, and has reliability and validity in the detection of adverse symptoms in clinical research 38 . Additional research is warranted to inform the selection of PRO-CTCAE items for given populations and contexts: on methods for optimizing patient response rates to surveys, particularly in hard-to-reach patient populations; on how to optimally map PRO-CTCAE scores to CTCAE grades; and on how best to include both health-related quality of life (HRQoL) tools and the PRO-CTCAE in a given trial would all be very useful.
The PRO-CTCAE approach differs from traditional HRQoL measurements in several ways, which have been outlined previously 9 . Briefly, the item library for the PRO-CTCAE contains over 100 questions relating to toxicity, and these items have all been individually validated. The PRO-CTCAE includes questions on phenomena such as lower-extremity oedema and bedsores, which are, generally, not included in HRQoL measurement tools. PRO-CTCAE questions are intended for frequent, regular administration in trials, with analyses akin to standard assessment of adverse events (defined as the proportion of patients experiencing each maximum toxicity grade post-baseline, expressed as a proportion) versus HRQoL, which usually includes before versus after assessments comparing mean values from two or more study arms. The purpose of the PRO-CTCAE is to improve the precision and patient-centeredness of symptomatic adverse event assessment 9 . Traditional HRQoL validation tools are generally intended to assess the extent of treatment benefits through comparisons between arms post-baseline through to global scores, or through the assessment of known disease-related symptoms.
PRO-CTCAE is currently being used in clinical trials and observational studies by numerous early adopters of this approach, and can be requested through a Materials Transfer Agreement with the NCI. Ideally, in the future, the PRO-CTCAE will be freely
PRO-CTCAE
In 2008 the NCI began developing a PRO version of the CTCAE in order to bring the patient perspective on toxicity reporting into widespread use in oncology 9 . The PRO-CTCAE was developed by a group of multidisciplinary collaborators under a contract with the NCI, with substantial input from both the NCI and the FDA. The PRO-CTCAE consists of a library of 78 toxicities mapped to the CTCAE, with up to three patient questions per toxicity. These patient questions were developed with extensive qualitative patient input including cognitive interviewing 6 , as well as quantitative evaluation of measurement properties 35, 36 . PRO-CTCAE items, overall, are effective indicators of patient symptoms, and equivalence has been found between paper, web and automated telephone administration of these items 9 . In addition to English, translations into Spanish, German, Danish, Italian, and Japanese currently exist, with additional translations currently in progress.
Evidence presented at the ISOQOL international meeting in 2015 demonstrates that use of the PRO-CTCAE better delineates the occurrence of symptomatic adverse events between study arms 27 . This conclusion is based on findings from multicentre, cooperative group research, with a greater number of statistically significant differences between study arms detected with the use of reporting by patients compared with reporting by clinicians 27 . Additionally, in evaluations available with a simple online registration process to remove any barriers to use, just as the CTCAE is currently freely available. Broad integration of the PRO-CTCAE into clinical trials in oncology will enable the organic development of methods for analysis of this information, and implementation of the findings within the research community, as has successfully occurred for the CTCAE.
Conclusions
Direct reporting of symptomatic toxicities by patients provides the opportunity to improve the precision, reliability and validity of the reporting of treatment-related toxicities in clinical research. This approach can generate information for future use by patients facing treatment decisions, based entirely on the experiences of patients like themselves, who participated in clinical trials. The US NCI has developed a patient-reported outcomes version of the CTCAE (the PRO-CTCAE) 39 , which offers a tangible approach to enhance the patient-centeredness of clinical trials in oncology and anticancer drug development.
